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Anti-idiotypic antibodies that bind at the active site of an anti-
tumour antibody have the potential to act as surrogate antigens,
thus stimulating immune responses against tumour antigens.
105AD7 is a human monoclonal anti-idiotypic antibody that was
derived from a cancer patient (Austin et al, 1989) who had
received radiolabelled 791T/36 antibody for diagnostic imaging of
his colorectal cancer metastases. The 791T/36 antibody has
recently been shown to bind to CD55 (Spendlove et al, 1999) a
complement regulatory protein. This antigen is over-expressed by
tumours presumably to protect them from complement-mediated
lysis. 105AD7 has been shown to bind at the combining site of
791T/36 and can thus mimic CD55. 
A phase I clinical trial with 105AD7 precipitated on alum
showed that anti-tumour T cell responses could be induced in
advanced colorectal cancer patients with no associated toxicity.
T cell responses included antigen-specific blastogenesis, enhanced
serum IL-2 production (Robins et al, 1991) and activation of
both helper and cytotoxic T cells (Durrant et al, 1999).
Furthermore survival of these patients was impressive (12
months) in a patient population with extensive liver metastases.
This was significantly longer than contemporary control patients
(Denton et al, 1994). A second trial evaluated 105AD7 in the
neoadjuvant setting. Patients with primary colorectal cancer
were immunized at diagnosis and then boosted post surgical
resection. Results showed significant infiltration of helper T
cells and natural killer cells (Durrant et al, 2000a, 2000b)
expressing the activation marker CD25 (Maxwell-Armstrong et
al, 1999) at the tumour site relative to controls. This was associ-
ated with an increase in tumour cell apoptosis in trial patients
(Amin et al, 2000). Furthermore enhanced tumour killing by both
natural killer cells and T cells has been seen following immu-
nization with 105AD7 (Durrant et al, 1994). The apparent
survival benefit observed in the Phase I study was therefore
evaluated in a double blind randomized trial of 105AD7 antibody
precipitated on alum versus an alum control vaccination. 
MATERIALS AND METHODS 
A randomized, double blind, placebo-controlled study was
performed comparing 105AD7 on alum treatment against alum
placebo alone. 
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Entry criteria included: patients with colorectal carcinoma with
evidence of a histologically confirmed inoperable recurrence, or
the presence of multiple metastatic lesions on imaging; a
minimum life expectancy of 3 months, and a World Health
Organization (WHO) performance grading of 0–2. Exclusion
criteria included acute intercurrent illness and autoimmune or
haematological disorders. Patients had not received chemotherapy
in the previous 3 months, or radiotherapy within 1 month
of commencement of the trial. Written informed consent was
obtained from all patients, and the trial approved by local ethics
committees. 
Clinical protocol 
Patients were recruited in 1 of 4 participating centres (Nottingham,
Leeds, Newcastle and Hull), between April 1994 and October
1996. At trial entry patient demographic data was collected, base-
line disease assessed, and WHO performance status recorded.
Patients received 10 mg of 105AD7/placebo intradermally and 
100 mg of 105AD7/placebo intramuscularly at trial entry, 6 and 12
weeks. All vaccinations were given into the shoulder. Routine
blood tests were performed prior to immunization (full blood
count, urea and electrolytes, liver function tests and carcinoembry-
onic antigen). At trial entry and 12 weeks, a chest X-ray and CT
scan were performed where possible. On each visit weight and
performance status were recorded, and any toxicity or adverse
events related to use of the 105AD7/placebo noted. Any new
medication or treatment instituted while on study was recorded.
Patients were not routinely followed up following the third dose of
105AD7/placebo. 
Monoclonal antibody 
Clinical grade monoclonal antibody was prepared as previously
described (Robins et al, 1991), using the guidelines of the Cancer
Research Campaign. 100 mg and 10 mg vials of 105AD7 were
indistinguishable to the naked eye from alum placebo. Stratified
randomization was in blocks of 6, by centre. 
Statistical analysis
It was calculated that to demonstrate a 22% improvement in
survival at the level P < 0.05, and a power of 90%, 161 patients
would need to be randomized into the 2 arms of the study. This
formed the basis of our sample size. 
SAS (version 6.0) was used for all data summary and analysis.
Survival in days was calculated from the date of randomization to
date of death or censoring, whichever came first. The censoring
date was taken as 21 February 1997. A secondary analysis was
also carried out where survival was measured from date of diag-
nosis of advanced disease to date of death or censoring. Survival
curves were constructed using the Kaplan–Meier method and
compared using the log rank test, and a Cox proportional hazards
method was used in the multivariate analysis. All P values
were two-sided; P values  ≤ 0.05 were considered statistically
significant. 
RESULTS 
A total of 162 patients were enrolled in the 4 trial centres, between
April 1994 and October 1996. 85 patients received 105AD7, and
77 alum placebo. 105AD7 and placebo arms were comparable in
terms of age, sex ratio, and grade, stage and site of tumour (Table
1). The mean time from diagnosis of advanced disease, and date of
randomization was almost identical in the 2 groups – 277.1 and
278.6 days, respectively. Time from resection of primary tumour
to date of randomization was 640.8 days in patients receiving
105AD7, and 803.7 days in placebo. Baseline disease was similar
in both groups, with the majority of patients having liver or lung
metastases (Table 2). Disease was not confined to 1 anatomic site,
and approximately 50% of patients had disease in 2 or more
distinct anatomic areas (Table 3). Overall compliance was poor,
with early progression resulting in only 54% and 60% of patients
receiving 3 doses of 105AD7/placebo respectively (Table 4).
Adjuvant radiotherapy was given to 10 patients in both 105AD7
and placebo arms, and in 13 patients in each group, as treatment
for advanced disease. 11 patients immunized with 105AD7
received adjuvant chemotherapy, as compared with 13 in placebo
patients. 30 and 21 patients in 105AD7 and placebo groups
received chemotherapy as treatment for their advanced disease. 
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Table 1 Demographics of patients recruited 
105AD7 Placebo
n = 85 n = 77 
Age Mean (SD) 63.3 (11.9) 62.2 (11.2) 
Range 27–85 33–85 
Sex Male 51 40 
Female 34 37 
Grade of primary tumour Well 3 4 
Moderate/well 3 2 
Moderate 43 42 
Moderate/poor 1 3 
Poor 5 8 
Missing 30 18 
Dukes stage of primary tumour A 2 2 
B 14 13 
C 35 33 
D 26 26 
Missing 8 3 
Site of primary tumour Colon 48 46 
Rectum 36 31 
Missing 1 0 
Table 2 Baseline disease at date of randomization 
105AD7 Placebo 
Liver metastases 61 (72) 50 (65) 
Lung metastases 27 (32) 20 (26) 
Primary tumour 10 (12) 6 (8) 
Local recurrence 19 (22) 30 (39) 
Regional nodes 13 (15) 10 (13) 
Bone metastases 5 (6) 1 (1) 
Skin metastases 2 (2) 2 (3) 
Brain metastases 1 (1) 1 (1) 
Malignant ascites 3 (4) 3 (4) 
Soft tissue metastases 0 4 (5) 
Peritoneal metastases 9 (11) 7 (9) 
Other 2 (2) 3 (4) 
Figures in parentheses represent percentages. The number of deaths from the date of randomization was 71
and 63 in 105AD7 and placebo arms respectively. There were 3
serious adverse events (SAE) – 2 in the placebo, and 1 in the
105AD7 arm. These were classified as CTC grade 3, and all were
felt unlikely to be due to 105AD7. As might be expected from a
group of patients with advanced disease, WHO performance status
gradually deteriorated throughout the study period. 
The median survival from the date of randomization in the
univariate analysis was 124 and 184 days in the 105AD7 and
placebo groups respectively (P = 0.38), as compared with figures
of 456 and 486 days from the date of diagnosis of advanced
disease (P = 0.82) (Figures 1 and 2). A similar analysis was
performed restricted to patients who had received 2 or more doses
of vaccine/placebo. Median survivals from randomization date
were 213 and 239 days in 105AD7 and control groups (P = 0.69),
and from diagnosis of advanced disease 511 and 486 days respec-
tively (P = 0.60). 
A multivariate analysis was performed both on an intention to
treat basis, and restricted to patients who had received at least 2
doses. These were performed from trial entry, and date of diag-
nosis of advanced disease. The only variables found to signifi-
cantly prolong survival were chemotherapy and radiotherapy, as
would be expected, and the absence of liver metastases. Mean
values for urea and electrolytes remained within normal limits in
both trial and control patients throughout the duration of the study.
Mean haemoglobin scores were low, confirming that patients were
anaemic when recruited, and that lymphocyte levels were at the
lower end of the normal range. 
DISCUSSION 
This study shows that immunization with the anti-idiotypic mono-
clonal antibody 105AD7 was well tolerated but did not confer a
survival advantage on patients with advanced colorectal cancer.
Patient characteristics were largely comparable in the 2 groups in
terms of age, sex, site and Duke’s stage of primary tumour. Median
times from diagnosis of advanced disease and inclusion into the
study were similar (172 and 179 days in 105AD7 and placebo
arms respectively). Interestingly the time between resection of the
primary tumour and trial entry was almost twice as long in the
placebo arm (13.7 months v 22.8 months). None of the patients in
the Phase I study received chemotherapy and thus survival from
diagnosis of advanced disease to death was very short. In contrast,
approximately 30% of patients in this trial received chemotherapy
as treatment for their advanced disease, and a multivariate analysis
showed that this significantly improved survival. The overall time
from date of diagnosis of advanced disease to death in patients in
this study was now 17 months, suggesting that 105AD7 immu-
nization was not commenced until very late in the disease course.
Only half of the patients survived long enough to receive the 3
planned doses of vaccine at 0, 6 and 12 weeks. In contrast, patients
in the phase I study could receive an immunization every 6 weeks
until death, with most patients receiving between 3 and 7 vaccina-
tions. Our recent studies have shown that with one exception
patients do not appear to make a memory response to 105AD7 but
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Table 3 Number of anatomical sites involved by tumour at date of
randomization 
Number of anatomical sites involved 105AD7 Placebo 
1 41 (48) 36 (47) 
2 26 (31) 26 (34) 
3 10 (12) 7 (9) 
4 2 (2) 5 (6) 
5 4 (5) 3 (4) 
6 2 (2) 0 
Figures in parentheses represent percentages. 
Table 4 Overall compliance in patients recruited 
105AD7 Placebo
Trial entry 85 (100) 77 (100) 
Week 6 63 (74) 59 (77) 
Week 12 46 (54) 46 (60) 
Figures in parentheses represent percentages. 
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Figure 1 Survival functions by treatment group, based on time from entry
into study
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Figure 2 Survival functions by treatment group, based on time from
diagnosis of advanced disease show a brisk immune response following each immunization
(Durrant et al 2000a) Thus the late stage of the colorectal cancer
disease and the low number of injections may have contributed to
the lack of survival benefit of 105AD7 in this trial. In addition
over 50% of patients had significant tumour burdens, with disease
in between 2 and 6 distinct sites. It has been hypothesized that
as disease advances the efficacy of immunotherapeutic agents
decreases (Jacob et al, 1997). 
Since the inception of this study we have immunized over 70
potentially less immunosuppressed patients with primary
colorectal cancer, and found evidence of a number of immune
responses. These include autologous tumour cell killing (Durrant
et al, 1994), upregulation of the IL-2 receptor (Buckley et al, 1995;
Maxwell-Armstrong et al, 1999) and significant infiltration of
CD4+ lymphocytes and NK cells (Durrant et al, 2000b). These
responses have correlated with increased apoptosis of tumour cells
in trial patients relative to controls (Amin et al, 2000). These find-
ings are of interest, and suggest an immune response may be
developing in patients with minimal residual disease. This is one
area where future activity will concentrate, though clearly the
bottom line is whether patients live longer or not. 
This trial highlights the problem of assessing the efficacy of
cancer vaccines in advanced disease patients – clearly there was
no evidence of survival advantage in this randomized study. It may
be difficult to generate a sustained immune response such that the
balance between activated T cells and tumour burden is tipped
in favour of tumour regression. Furthermore recent evidence
suggests that if naive T cells receive a signal from MHC/peptide
without a constimulatory signal they can be anergized. As tumours
express MHC/peptide in the absence of costimulation they will
effectively anergize naive T cells reducing the pool of T cells
available for stimulation by a vaccine. More aggressive immuniza-
tion with a stronger Th1 adjuvant than alum may help rectify the
balance. Future studies are therefore using BCG as an adjuvant
and reconfiguring the anti-idiotype as a DNA vaccine. It remains
to be seen if these approaches can be shown to be of benefit,
though clearly persevering with our current vaccine in patients
with advanced disease would not be sensible. 
The apparent survival advantage of immunization with 105AD7
observed in our initial phase I trial was not confirmed in a double
blind randomized trial. However 105AD7 does induce significant
tumour cell apoptosis in a neoadjuvant trial. More aggressive
immunization with a more potent immune adjuvant in the treat-
ment of patients with minimal residual disease is therefore
planned. 
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